MCP Master Income Trust (MXTNB) Cotización

Trump rapidly fortifies US borders with plans for 10,000 troops, immediate deportation of illegal crossers
By Jennie Taer and Chris Nesi Published Jan. 22, 2025, 8:24 p.m. ET

Welcome to President Trump’s fortress America.

In just three days, the commander in chi

Let me guess…4 reasons. Competition, cash burn, no big announcements from all of their B2B hype and the relaunch was a dud.

All of which is being realized now that it is going to be awhile before revenues will truly significantly increase to raise the sp to a gain on original investe

Good riddance...
https://nypost.com/wp-content/uploads/sites/2/2025/01/JANUARY23.P1_LCF.jpg?resize=400,441&quality=90&strip=all&w=750

Make no mistake dudes!! FOXO AI world leader in epigenetic AI https://foxotechnologies.com/research/#tools-and-resources


https://pubmed.ncbi.nlm.nih.gov/33208060/

https://www.mcpdigitalhealth.org/article/S2949-7612(23)00065-2/fulltext

https://clin

Thanks! Keep us posted!

Equally good.

Make sure LP doesn't disappoint and take another 2-3 years for the next major milestone post UK approval. Fluff PRs like Oncovir partnership doesn't count. I’d say even combo trial announcement will not have any impact as the markets already know. However, if big pharma announces the combo trial new

19.5 here.

That's good, but I'm compelled to post this one frequently because It's Pure Gold:

“Far more money has been lost by investors trying to anticipate corrections,
than lost in the corrections themselves.” Ascribed to Peter Lynch.

PLRZ News Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

PLRZ News Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Sure you do 🤡

Trump's ICE racks up hundreds of arrests, including illegal immigrants arrested for horror crimes

Over 460 arrests were made in the first 33 hours of the administration

https://www.foxnews.com/politics/trumps-ice-racks-up-hundreds-arrests-including-illegal-immigrants-ar

Downgrades - Jan 23, 2025

$VEEV - Goldman Sachs: Buy to Sell ($200 from $261)
$SAM - Piper Sandler: Overweight to Neutral ($275 from $370)
$EA - BMO Capital: Outperform to Market Perform ($145 from $160)
$EA - Raymond James: Outperform to Market Perform
$EA

Upgrades - Jan 23, 2025

$OPCH - Jefferies: Hold to Buy ($35 from $26)
$BOOT - KeyBanc: Sector Weight to Overweight ($190)
$RVLV - KeyBanc: Sector Weight to Overweight ($37)
$NFLX - Arete: Sell to Neutral ($833)
$NFLX - Wolfe: Peerperform to Outperform ($1,1

now everything is clear here ☺️

That's all they do. Blame everyone and everything for their misfortunes except for the company......smh

You can't even get the numbe right. It was over 90,000 emails. Lot's of folks were swindled in this scheme. Lot's of angry investors that lost it all.

2027 is the year that $AHRO is scheduled to give today's investors a very nice return imho

No could would should dude!! Make no mistake FOXO World leader in epigenetics AI Technologies
https://www.nature.com/articles/s41467-025-56331-w

Pump and dump?

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV – January 23rd, 2025 – Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), an innovative topical pharmaceutical research and development company,

today announces

Waiting for the 3rd cohort news results!!!can be life changing

IBM
IBM price target raised to $233 from $227 at JPMorgan
JPMorgan raised the firm's price target on IBM to $233 from $227 and keeps a Neutral rating on the shares as part of a Q4 earnings preview. The firm expects "healthy" software and artificial intelligence business for Q4, offs

good morning 🌞🌞🌞🌞🌞🌞🌞🌞🌞🌞🌞